Skip to main content

Table 1 Clinicopathological features of the general cohort population

From: Digital imaging-assisted quantification of H3K27me3 immunoexpression in luminal A/B-like, HER2-negative, invasive breast cancer predicts patient survival and risk of recurrence

Variables

N

%

Luminal subtypes

 A-like

66

41.3

 B-like

94

58.8

 IDC (versus others)

133

83.1

Grade

 G1

22/158

13.9

 G2

81/158

51.3

 G3

55/158

34.8

pT Stage

 pT1

55/148

37.2

 pT2

87/148

58.8

 pT3-p/cT4a

6/148

4.0

pN Stage

 pN-

68/153

44.4

 pN+

85/153

55.6

 pN+≥ 4 nodes

35/85

41.2

Adjuvant Treatment

 Adjuvant CT

63/100

63.0

 Adjuvant RT

117/143

81.8

 Adjuvant ET

128/132

97.0

 Adjuvant TMX only

93/128

72.7

 Adjuvant TMX + AI

34/128

26.6

 Adjuvant TMX + GOS

1/128

0.8

Recurrence

42

26.3

 Early recurrence

22/42

52.4

 ET-resistant recurrence

24/42

57.1

 Systemic recurrence

33/42

78.6

Death

35

21.9

  1. n = 160 unless otherwise specified. aT3 and T4 cases analyzed conjointly due to low N (see text for further details) Abbreviations: AI Aromatase inhibitor, CT Chemotherapy, ET Endocrine treatment, GOS Goserelin, IDC Invasive ductal carcinoma, RT Radiotherapy, TMX Tamoxifen
Back to article page

Molecular Medicine

ISSN: 1528-3658